What is CNSP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CNSP?

P/E (TTM) is n/a and 52-week range is $1.90 to $10.54 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CNSP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CNSP?

The company profile lists net income (TTM) near -$34M, EPS (TTM) near -$23.14 when available from the market-data feed. Figures are informational and may lag live markets.

Where is CNS Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Houston, Texas, US, 1.5M shares outstanding, ISIN US18978H5081 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

CNS Pharmaceuticals Inc

$CNSP

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.

Employees

Website

cnspharma.com/

IPO

2019-11-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US18978H5081

Headquarters

Houston, Texas, US

Shares outstanding

1.5M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

19.19%

Browse other companiesFree AI scores and summaries for more stocks

CNS Pharmaceuticals Inc (CNSP) Stock Analysis & Quote